Eli Lilly Introduces Tanstrive in India to Expand Precision Oncology Treatment
In a significant advancement for cancer care in India, Eli Lilly and Company India has launched Tanstrive (Selpercatinib) after receiving marketing authorization from the Central Drugs Standard Control Organisation (CDSCO). The targeted therapy is designed for patients with RET-altered cancers, offering a precision medicine approach that specifically targets genetic mutations responsible for tumor growth.
The launch marks an important milestone in India’s oncology landscape by making a highly selective RET inhibitor available to eligible patients suffering from advanced or metastatic cancers associated with RET gene alterations.
What is Tanstrive (Selpercatinib)?
Tanstrive is an oral selective RET inhibitor developed to block abnormal RET signaling pathways that drive the growth and spread of certain cancers. Unlike conventional chemotherapy, Tanstrive specifically targets cancer cells with RET gene alterations while minimizing damage to healthy cells.
The medicine is available in the following strengths:
- 40 mg
- 80 mg
- 120 mg
- 160 mg
The tablets are administered twice daily according to the treating oncologist’s recommendation.
Price of Tanstrive in India
Eli Lilly has priced Tanstrive at ₹2.15 lakh per box.
- Price: ₹2.15 lakh per box
- Treatment Duration per Pack: 14 days
- Administration: Oral tablets taken twice daily
What are RET Gene Alterations?
RET (Rearranged During Transfection) gene alterations are rare but important genetic abnormalities that can cause uncontrolled cell growth, leading to several types of cancers.
Although these mutations occur in a relatively small percentage of cancer patients, identifying them through genomic testing allows doctors to prescribe highly targeted therapies like Tanstrive, improving treatment outcomes while reducing unnecessary exposure to ineffective treatments.
Approved Indications of Tanstrive
Tanstrive has been approved in India for the treatment of the following conditions:
1. RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
For adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a RET gene fusion.
2. Medullary Thyroid Cancer (MTC)
For adults and children aged 2 years and above with advanced or metastatic medullary thyroid cancer carrying a RET mutation and requiring systemic therapy.
3. Advanced RET Fusion-Positive Thyroid Cancer
For adults and pediatric patients (2 years and older) with advanced thyroid cancer having a RET gene fusion that no longer responds to radioactive iodine therapy.
4. RET Fusion-Positive Solid Tumours
For adults and children (2 years and older) with locally advanced or metastatic RET fusion-positive solid tumors that have progressed following prior systemic treatment or when no satisfactory alternative treatment exists.
Clinical Benefits of Tanstrive
Clinical studies have shown that Tanstrive provides:
- Rapid tumor response
- Durable clinical benefits
- Activity against brain metastases (CNS involvement)
- Precision targeting of RET-altered cancer cells
- Improved treatment outcomes for eligible patients
These characteristics make Tanstrive an important advancement in precision oncology.
Importance of Genomic Testing
Experts emphasize that comprehensive genomic testing plays a crucial role in identifying patients who may benefit from targeted therapies like Tanstrive.
Since RET alterations cannot be detected through routine imaging or standard pathology alone, molecular profiling is essential before initiating treatment.
Genomic testing helps oncologists:
- Detect RET gene fusions and mutations
- Select the most appropriate targeted therapy
- Avoid unnecessary treatments
- Personalize cancer management
Expert Opinion
According to Winselow Tucker, President and General Manager, Eli Lilly and Company India, the launch of Tanstrive reflects Lilly’s commitment to bringing innovative, evidence-based therapies to patients with RET-altered cancers in India.
Dr. Rahul Kapur, Senior Director, Medical, Eli Lilly India, highlighted that Tanstrive is the first and only selective RET inhibitor approved in India for RET-altered solid tumors irrespective of tumor type. He also stressed the growing importance of comprehensive genomic testing in precision oncology.
Why is This Launch Important?
RET alterations occur in only a small percentage of cancers, including approximately 1–2% of Non-Small Cell Lung Cancer (NSCLC) cases in India. However, identifying these patients enables access to personalized treatment strategies that can significantly improve outcomes.
The availability of Tanstrive strengthens India’s precision oncology ecosystem by expanding access to advanced targeted therapies based on molecular diagnostics rather than tumor location alone.
Key Highlights
- CDSCO-approved targeted cancer therapy
- First selective RET inhibitor approved in India for RET-altered solid tumors
- Oral tablets available in four strengths
- Price: ₹2.15 lakh per 14-day treatment pack
- Targets RET gene alterations
- Effective for NSCLC, Medullary Thyroid Cancer, Thyroid Cancer, and RET fusion-positive solid tumors
- Supports precision oncology through biomarker-based treatment
Conclusion
The launch of Tanstrive (Selpercatinib) by Eli Lilly marks a major advancement in India’s cancer treatment landscape. By specifically targeting RET gene alterations, the therapy offers a personalized treatment option for patients with advanced cancers who may benefit from precision medicine.
As genomic testing becomes more widely adopted, therapies like Tanstrive are expected to play an increasingly important role in improving survival and quality of life for patients with genetically driven cancers.
Recommended Products
